Stetson Van Matre Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
unknown
Research Areas
Biography and Research Information
OverviewAI-generated summary
Stetson Van Matre's research investigates strategies to enhance the effectiveness of cancer therapies, particularly focusing on pancreatic and rectal cancers. His work has explored the radiosensitization of pancreatic cancer through the inhibition of Cyclin-dependent kinase 1 (CDK1). Additionally, his research has examined the potential of methionine restriction to radiosensitize KRAS mutant rectal cancer. He also studies the therapeutic application of nanoparticles, such as Amyloid Targeting-Gold Nanoparticles, in rescuing pancreatic islet β-cells from amyloid fibrils and restoring insulin homeostasis.
Van Matre has published five research articles and has a h-index of 2 with 10 citations. His work involves collaborations with researchers from the University of Arkansas for Medical Sciences, including Robin Eluvathingal, Henrique Rodrigues, and Lokesh Akana, as well as Óscar Zúñiga from the University of Arkansas at Little Rock.
Metrics
- h-index: 2
- Publications: 5
- Citations: 13
Selected Publications
-
Amyloid Targeting-Gold Nanoparticles-Assisted X-ray Therapy Rescues Islet β-Cells from Amyloid Fibrils and Restores Insulin Homeostasis (2025)
-
Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1 (2024)
-
Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1 (2024)
-
Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer (2023)
Collaboration Network
Top Collaborators
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- OC-0427 Targeting Cyclin-Dependent Kinase 1 to Radiosensitize Pancreatic Cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- OC-0427 Targeting Cyclin-Dependent Kinase 1 to Radiosensitize Pancreatic Cancer
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- OC-0427 Targeting Cyclin-Dependent Kinase 1 to Radiosensitize Pancreatic Cancer
- OC-0427 Targeting Cyclin-Dependent Kinase 1 to Radiosensitize Pancreatic Cancer
- OC-0427 Targeting Cyclin-Dependent Kinase 1 to Radiosensitize Pancreatic Cancer
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
- Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1
Similar Researchers
Based on overlapping research topics